TRACON Pharmaceuticals Company Profile (NASDAQ:TCON)

About TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Symbol: NASDAQ:TCON
CUSIP: N/A
Web: www.traconpharma.com

Capitalization:

Market Cap: $47.34 million
Outstanding Shares: 16,609,000

Average Prices:

50 Day Moving Avg: $3.42
200 Day Moving Avg: $4.48
52 Week Range: $2.75 - $7.86

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.95
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $2.87 million
Price / Sales: 16.49
Book Value: $1.39 per share
Price / Book: 2.05

Profitability:

EBIDTA: ($26,510,000.00)
Net Margins: -750.91%
Return on Equity: -137.76%
Return on Assets: -72.55%

Debt:

Debt-to-Equity Ratio: 0.27%
Current Ratio: 2.77%
Quick Ratio: 2.77%

Misc:

Average Volume: 62,353 shs.
Beta: 2.77
Short Ratio: 4.03

Frequently Asked Questions for TRACON Pharmaceuticals (NASDAQ:TCON)

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The company earned $0.63 million during the quarter, compared to analysts' expectations of $0.92 million. TRACON Pharmaceuticals had a negative return on equity of 137.76% and a negative net margin of 750.91%. View TRACON Pharmaceuticals' Earnings History.

Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2017?

4 analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their predictions range from $10.00 to $15.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $13.00 in the next twelve months. View Analyst Ratings for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

Some companies that are related to TRACON Pharmaceuticals include Cellular Biomedicine Group (CBMG), Verastem (VSTM), ArQule (ARQL), Infinity Pharmaceuticals (INFI), Ophthotech Corp (OPHT), Microbot Medical (MBOT), AVEO Pharmaceuticals (AVEO), Actinium Pharmaceuticals (ATNM), Mirati Therapeutics (MRTX), aTyr Pharma (LIFE), Nexvet Biopharma plc (NVET), Akari Therapeutics PLC (AKTX), Brainstorm Cell Therapeutics (BCLI), Intec Pharma Ltd (NTEC), Regulus Therapeutics (RGLS), Navidea Biopharmaceuticals (NAVB), Xenon Pharmaceuticals (XENE) and Imprimis Pharmaceuticals (IMMY).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who owns TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (17.07%), Eventide Asset Management LLC (5.57%), Vanguard Group Inc. (1.11%), Candriam Luxembourg S.C.A. (0.88%), Renaissance Technologies LLC (0.39%) and Stifel Financial Corp (0.19%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, H Casey Logan, Jafco Super V3 Investment Limi, Peter W Sonsini and Ronald L Shazer. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Who bought TRACON Pharmaceuticals stock? Who is buying TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Stifel Financial Corp and Geode Capital Management LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy TRACON Pharmaceuticals stock?

Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TRACON Pharmaceuticals stock cost?

One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $2.85.

Consensus Ratings for TRACON Pharmaceuticals (NASDAQ:TCON) (?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$13.00 (356.14% upside)

Analysts' Ratings History for TRACON Pharmaceuticals (NASDAQ:TCON)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
1/5/2017	Stifel Nicolaus	Reiterated Rating	Buy	$14.00	N/A
1/3/2017	Wells Fargo & Co	Downgrade	Outperform -> Market Perform		N/A
12/21/2016	Jefferies Group LLC	Initiated Coverage	Buy	$10.00	N/A
8/19/2016	BTIG Research	Initiated Coverage	Buy	$15.00	N/A
2/1/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform		N/A
10/8/2015	Roth Capital	Reiterated Rating	Buy		N/A

(Data available from 5/28/2015 forward)

Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)

Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Earnings History by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/10/2017	Q1 2017	($0.47)	($0.44)	$0.92 million	$0.63 million	View	N/A
8/10/2016	Q2	($0.62)	($0.68)	$1.27 million	$0.81 million	View	Listen
5/11/2016	Q1	($0.70)	($0.54)		$1.21 million	View	Listen
2/18/2016	Q4	($0.62)	($0.91)		$1.40 million	View	Listen
11/3/2015	Q3	($0.51)	($0.53)	$1.06 million	$1.18 million	View	Listen
8/5/2015	Q215	($0.42)	($0.24)	$1.02 million	$4.20 million	View	Listen
5/13/2015	Q1	($0.37)	($0.50)		$1.13 million	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)

2017 EPS Consensus Estimate: ($1.86)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.45)	($0.45)	($0.45)
Q2 2017	1	($0.51)	($0.51)	($0.51)
Q3 2017	1	($0.44)	($0.44)	($0.44)
Q4 2017	1	($0.46)	($0.46)	($0.46)

(Data provided by Zacks Investment Research)

Dividend History for TRACON Pharmaceuticals (NASDAQ:TCON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for TRACON Pharmaceuticals (NASDAQ:TCON)

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 24.03%

Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/29/2016	Peter W Sonsini	Major Shareholder	Buy	869,565	$5.75	$4,999,998.75
6/3/2016	Ronald L Shazer	Insider	Sell	1,003	$7.48	$7,502.44
10/16/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	1,500	$9.90	$14,850.00
10/15/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	5,300	$10.16	$53,848.00
10/13/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	3,168	$10.01	$31,711.68
10/9/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	1,448	$10.01	$14,494.48
10/8/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	21,920	$10.10	$221,392.00
10/5/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	15,100	$10.08	$152,208.00
9/25/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	7,600	$12.13	$92,188.00
9/24/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	22,303	$12.99	$289,715.97
9/22/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	39,426	$14.02	$552,752.52
9/21/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	18,200	$14.48	$263,536.00
9/18/2015	Charles Theuer	CEO	Sell	10,000	$17.34	$173,400.00
9/18/2015	H Casey Logan	insider	Sell	5,000	$17.34	$86,700.00
9/17/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	42,344	$11.78	$498,812.32
9/14/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	60,038	$11.78	$707,247.64
9/10/2015	Charles Theuer	CEO	Sell	3,516	$12.00	$42,192.00
9/9/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	12,000	$10.71	$128,520.00
9/8/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	5,700	$10.47	$59,679.00
9/4/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	6,600	$10.48	$69,168.00
9/3/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	15,300	$10.51	$160,803.00
9/1/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	14,000	$10.42	$145,880.00
8/24/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	3,000	$11.00	$33,000.00
8/20/2015	Jafco Super V3 Investment Limi	major shareholder	Sell	10,683	$11.36	$121,358.88
8/18/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	11,174	$11.71	$130,847.54
8/13/2015	Jafco Super V3 Investment Limi	Major Shareholder	Sell	9,361	$11.60	$108,587.60
2/4/2015	M James Barrett	Major Shareholder	Buy	500,000	$10.00	$5,000,000.00

(Data available from 1/1/2013 forward)

Headline Trends for TRACON Pharmaceuticals (NASDAQ:TCON) Latest Headlines for TRACON Pharmaceuticals (NASDAQ:TCON)

Source:

Date	Headline
	Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) to Announce -$0.53 EPS www.americanbankingnews.com - May 26 at 7:36 AM
	TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting finance.yahoo.com - May 26 at 7:35 AM
	TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer globenewswire.com - May 24 at 8:56 AM
	TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer finance.yahoo.com - May 24 at 8:56 AM
	FY2019 EPS Estimates for TRACON Pharmaceuticals Inc Raised by Jefferies Group (TCON) www.americanbankingnews.com - May 15 at 10:02 AM
	Edited Transcript of TCON earnings conference call or presentation 10-May-17 8:30pm GMT finance.yahoo.com - May 12 at 2:13 AM
	TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia finance.yahoo.com - May 12 at 2:13 AM
	TRACON Pharmaceuticals Inc (TCON) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS www.americanbankingnews.com - May 11 at 4:28 PM
	TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update finance.yahoo.com - May 11 at 1:55 AM
	Tracon reports 1Q loss finance.yahoo.com - May 11 at 1:55 AM
	Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - May 10 at 10:26 AM
	Zacks: Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $920,000.00 www.americanbankingnews.com - May 4 at 10:56 AM
	TRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017 finance.yahoo.com - May 3 at 6:22 PM
	TRACON Pharmaceuticals (TCON) Earns Media Impact Rating of -0.06 www.americanbankingnews.com - May 1 at 4:42 PM
	TRACON Pharmaceuticals (TCON) Receives Daily News Impact Rating of -0.25 www.americanbankingnews.com - April 27 at 3:09 PM
	TRACON Pharmaceuticals (TCON) Given Daily Media Impact Rating of -0.07 www.americanbankingnews.com - April 19 at 9:47 AM
	TRACON Pharmaceuticals Inc (TCON) Sees Significant Drop in Short Interest www.americanbankingnews.com - April 18 at 7:48 PM
	Zacks: Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $920,000.00 www.americanbankingnews.com - April 13 at 11:31 AM
	TRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.47 Per Share www.americanbankingnews.com - April 11 at 6:07 PM
	TRACON Awarded ‘Most Innovative Trial Design’ for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards finance.yahoo.com - April 10 at 7:39 PM
	TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting us.rd.yahoo.com - March 27 at 7:23 PM
	Tracon Pharmaceuticals Inc. (TCON) Is Rising On Aspire Capital Fund Agreement www.rttnews.com - March 14 at 7:40 PM
	TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC finance.yahoo.com - March 14 at 7:40 PM
	4:06 pm Tracon Pharmaceuticals announces $21 million common stock purchase agreement with Aspire Capital Fund finance.yahoo.com - March 14 at 7:40 PM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ biz.yahoo.com - March 14 at 7:40 PM
	TRACON PHARMACEUTICALS, INC. Financials finance.yahoo.com - March 7 at 8:01 PM
	TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference - GlobeNewswire (press release) globenewswire.com - March 6 at 7:23 PM
	TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference finance.yahoo.com - March 6 at 7:23 PM
	Edited Transcript of TCON earnings conference call or presentation 28-Feb-17 9:30pm GMT finance.yahoo.com - March 1 at 11:24 PM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements biz.yahoo.com - March 1 at 9:35 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report biz.yahoo.com - March 1 at 9:35 AM
	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update us.rd.yahoo.com - February 28 at 7:47 PM
	Q4 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close biz.yahoo.com - February 28 at 11:37 AM
	TRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017 finance.yahoo.com - February 21 at 4:47 PM
	TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma finance.yahoo.com - February 16 at 7:59 PM
	Tracon Tanks on Brain Cancer Drug Failure (TCON) - Investopedia www.investopedia.com - February 13 at 8:39 PM
	Tracon Pharma Tanks on Brain Cancer Drug Failure www.investopedia.com - February 13 at 3:38 PM
	Health Care Sector Update for 02/10/2017: TCON,IMMU,SGEN,BSTG - Nasdaq www.nasdaq.com - February 12 at 1:18 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits biz.yahoo.com - February 11 at 8:17 PM
	Mid-Morning Market Update: Markets Open Higher; NVIDIA Beats Q4 Views www.nasdaq.com - February 11 at 5:05 AM
	TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma us.rd.yahoo.com - February 10 at 5:57 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin biz.yahoo.com - February 9 at 6:04 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - February 9 at 6:04 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos biz.yahoo.com - January 10 at 1:19 AM
	Tracon Pharmaceuticals: ~$5 Biotech Stock With Plenty Of Catalysts In 2017 seekingalpha.com - January 7 at 3:51 AM
	8:05 am Tracon Pharmaceuticals receives special protocol assessment agreement from FDA for phase 3 clinical trial of TRC105 in Angiosarcoma us.rd.yahoo.com - January 3 at 9:21 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and biz.yahoo.com - December 22 at 3:58 AM
	Coverage initiated on Tracon Pharmaceuticals by Jefferies finance.yahoo.com - December 22 at 3:58 AM
	TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and biz.yahoo.com - December 14 at 5:46 AM